Clinical trials: Stage II Skin Cancer
Breast Cancer, PI3K, Alpelisib
SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer
SAFIR PI3K is an open-label multicenter phase II randomized trial, comparing alpelisib plus fulvestrant to maintenance chemotherapy in patient PIK3CA mutated with HR+/Her2- metastatic breast cancer who do not present progressive…
- Trial name
- SAFIR-PI3K (NCT03386162)
- Testing
- Alpelisib, Chemotherapy
- Where
- 14 sites in France
- Volunteers
- 31 people
- Sponsor
- UNICANCER
Breast Neoplasms
Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer
The purpose of the study is to see if the drug KU-0059436 (olaparib) is effective and well tolerated in treating participants with measurable breast cancer gene (BRCA)1- or BRCA2-positive advanced breast cancer and for whom no…
- Trial name
- ICEBERG 1 (NCT00494234)
- Testing
- Olaparib
- Where
- 17 sites in United States, Australia and 6 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Breast Cancer
Post-operative Radiation With IMRT in the Management of Stage IIB-III Breast Cancer
Research has shown that treatment with conventional radiation techniques and chemotherapy following mastectomy or breast conserving surgery has resulted in better rates of locoregional control and overall survival in stage…
- Trial name
- NCT00508352
- Testing
- Helical tomotherapy IMRT
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Ottawa Hospital Research Institute
Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I
Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors
This randomized double-blind clinical trial studied the effect of oral omega-3 fatty acid on atrophic vaginitis in postmenopausal breast cancer survivors (N=52).
- Conditions
- Ductal Breast Carcinoma in Situ, Breast Cancer, Stage I, Breast Cancer, Stage II, Breast Cancer, Stage III
- Trial name
- NCT02150525
- Testing
- omega-3 fatty acid, Questionnaire administration
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer
Cabozantinib for Metastatic Triple Negative BrCa
In this research study, we are looking at the anti-tumor effects of Cabozantinib (XL184) in metastatic breast cancer. Data suggest that MET expression and activation are important for initiation and progression of triple-negative…
- Trial name
- NCT01738438
- Testing
- Cabozantinib
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Dana-Farber Cancer Institute
Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype.
- Conditions
- Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv, Metastatic Breast Cancer
- Trial name
- NCT06062498
- Testing
- elacestrant, palbociclib, abemaciclib, ribociclib
- Where
- 3 sites in United States
- Volunteers
- 174 people
- Sponsor
- Northwestern University
Melanoma
Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib
This is a three-arm, open-label, randomised Phase II study to evaluate whether the different sequencing of dabrafenib and trametinib monotherapies and the upfront combination has an impact on translational or clinical activity in…
- Trial name
- NCT02314143
- Testing
- Dabrafenib, Trametinib
- Where
- 7 sites in France, Spain
- Volunteers
- 48 people
- Sponsor
- GlaxoSmithKline
Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss
The goal of this clinical research study is to learn if GSK2636771 given in combination with pembrolizumab can help to control the disease in patients with refractory (has not responded to treatment) metastatic melanoma.
- Trial name
- NCT03131908
- Testing
- GSK2636771, Pembrolizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Brain Metastases
FSRT in Breast Cancer Patients With Brain Metastases
Brain metastasis accounted for 10-15% of all breast cancer patients and even higher in patients with triple negative and HER2 overexpressed subtype.
- Trial name
- NCT04061408
- Testing
- Fractionated stereotactic radiotherapy(FSRT)
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Fudan University
Breast Cancer
Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease
RATIONALE: Collecting and storing samples of blood and tumor tissue from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Trial name
- NCT00898508
- Testing
- gene expression analysis, mutation analysis, proteomic profiling
- Where
- 3 sites in United States
- Volunteers
- 563 people
- Sponsor
- City of Hope Medical Center
Triple-negative Breast Cancer
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
We plan to explore the efficacy and safety of albumin-bound paclitaxel+carboplatin+Camrelizumab in neoadjuvant therapy for early TNBC patients, optimize the administration method and drug combination therapy.
- Trial name
- NCT06817525
- Testing
- 6*Nab-P (d 1)+6*Cb ( d 1)+6*PD1 (d 1), 6*Nab-P (d 1,8,15)+6*Cb ( d 1)+6*PD1 (d 1)
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Henan Cancer Hospital
Melanoma
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study
This study is for patients with advanced stage III or stage IV melanoma not adequately treated by surgery who have progressed after treatment with nivolumab or pembrolizumab.
- Trial name
- NCT02796352
- Testing
- High dose bolus interleukin-2 (HD IL2)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Ahmad Tarhini
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
- Trial name
- NCT06726148
- Testing
- ECI830, ribociclib, fulvestrant
- Where
- 33 sites in United States, Australia and 14 more
- Volunteers
- 280 people
- Sponsor
- Novartis Pharmaceuticals
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes
The purpose of this study is to determine whether cabazitaxel is effective in the treatment of metastatic breast cancer.
- Trial name
- NCT01693549
- Testing
- Cabazitaxel
- Where
- 17 sites in Greece
- Volunteers
- 84 people
- Sponsor
- Hellenic Cooperative Oncology Group
Breast Cancer
A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer
This is a Phase II, open-label, non-randomized study in patients with locally advanced or metastatic breast cancer. Each cycle will be 4 weeks in length. Patients will receive Abraxane weekly for 3 weeks.
- Trial name
- NCT00607438
- Testing
- Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane), Sorafenib (Nexavar)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Veeda Oncology
Breast Cancer
Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.
To determine the effects of endurance exercise training on cardiopulmonary fitness in breast cancer patients undergoing neoadjuvant chemotherapy.
- Trial name
- NCT00405678
- Testing
- Exercise Training, Chemo only
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Duke University
Breast Cancer
Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
RATIONALE: The monoclonal antibody trastuzumab can locate breast cancer cells that have HER2 on their surface and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00057993
- Testing
- trastuzumab, exemestane
- Sponsor
- Northwestern University
Prostate Cancer, Non-Small Cell Lung Cancer
Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors
This is a phase II trial of (RQ-07) in advanced solid tumors in prostate, breast or non-small cell lung cancer.
- Conditions
- Prostate Cancer, Non-Small Cell Lung Cancer, Breast Cancer
- Trial name
- NCT02538432
- Testing
- RQ-00000007, Gemcitabine
- Sponsor
- University of Maryland, Baltimore
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.